ICD-10 Coding for Extrapyramidal Symptoms(G21.11, G21.11B, G21.11N)
Learn about ICD-10 coding for extrapyramidal symptoms, including specific codes for drug-induced conditions like neuroleptic-induced parkinsonism.
Complete code families applicable to Extrapyramidal Symptoms
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| G25.9 | Unspecified extrapyramidal and movement disorder | Use when specific subtype cannot be determined after thorough evaluation. |
|
| G21.11 | Neuroleptic-induced parkinsonism | Use when parkinsonian symptoms are directly linked to neuroleptic drug use. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutExtrapyramidal Symptoms
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Extrapyramidal Symptoms.
Generalizing EPS without specifying symptoms
Impact
Clinical: May lead to inappropriate treatment decisions., Regulatory: Increased risk of audit and compliance issues., Financial: Potential for denied claims due to lack of specificity.
Mitigation
Educate clinicians on the importance of detailed documentation., Implement documentation templates.
Using G25.9 for specific drug-induced EPS
Impact
Reimbursement: Potential for reduced reimbursement due to lack of specificity., Compliance: Increased risk of audit due to unspecified coding., Data Quality: Decreased data accuracy for clinical research and reporting.
Mitigation
Identify and document specific symptoms and drug causation.
Unspecified EPS coding
Impact
High risk of audit if G25.9 is used without specific symptom documentation.
Mitigation
Provide training on documenting specific EPS symptoms and drug causation.